Tachibana Nobuko, Niiyama Yukitoshi, Yamakage Michiaki
From the Department of Anesthesiology, Sapporo Medical University School of Medicine, Hokkaido, Japan.
Eur J Anaesthesiol. 2014 Dec;31(12):701-7. doi: 10.1097/EJA.0000000000000154.
Target-controlled infusions (TCIs) of propofol are commonly used for general anaesthesia. The Marsh model pharmacokinetic parameter set incorporated in TCI devices for propofol could increase bias when used in obese patients.
The purpose of this study was to assess the optimal predicted blood concentration (Cp) of 4.0 μg ml of propofol using a correction formula including BMI and to evaluate the influences on propofol concentration in obese patients.
An open-label, comparative study.
Sapporo Medical University Hospital, Japan, from October 2011 to December 2013.
Seventy-five adults scheduled for elective surgery under general anaesthesia with the following exclusion criteria: less than 30 or more than 65 years of age; American Society of Anesthesiologists status 3 to 5; allergy to propofol; the daily use of psychoactive drugs; known or suspected drug or alcohol abuse; and cardiac, hepatic, renal or neurological impairment.
Propofol was administered and maintained at a Cp of 4.0 μg ml using a TCI device programmed with the Marsh pharmacokinetic model. Arterial blood samples were collected at 15, 30, 60, 90, 120, 150 and 180 min after the start of the infusion, and the measured propofol concentration (Cm) was determined. After calculation of the adjustment formula using the corrected Cp of 69 patients, we then applied the corrected Cp to five other obese patients.
The median performance error (MDPE) and median absolute performance error (MDAPE) were calculated to measure bias at each time point.
We analysed 333 samples from the 69 individuals. There was a significant correlation between BMI and Cm, which tended be greater than 4.0 μg ml in obese patients. Our new method improved MDPE and MDAPE from a range of 20 to 40 for both, to ranges of -11.3 to -1.8 and 8.8 to 11.5, respectively.
BMI influences blood propofol concentrations, leading to the possibility of overdosage of propofol in obese patients when the Marsh model is used to assess propofol concentration. Our new method using corrected Cp might improve this bias in obese, Japanese patients.
丙泊酚靶控输注(TCI)常用于全身麻醉。用于丙泊酚的TCI设备中纳入的Marsh模型药代动力学参数集在肥胖患者中使用时可能会增加偏差。
本研究旨在使用包含体重指数(BMI)的校正公式评估丙泊酚4.0μg/ml的最佳预测血药浓度(Cp),并评估其对肥胖患者丙泊酚浓度的影响。
一项开放标签的对照研究。
日本札幌医科大学医院,时间为2011年10月至2013年12月。
75例计划在全身麻醉下接受择期手术的成年人,排除标准如下:年龄小于30岁或大于65岁;美国麻醉医师协会(ASA)分级为3至5级;对丙泊酚过敏;每日使用精神活性药物;已知或疑似药物或酒精滥用;以及存在心脏、肝脏、肾脏或神经功能损害。
使用根据Marsh药代动力学模型编程的TCI设备给予并维持丙泊酚血药浓度为4.0μg/ml。在输注开始后15、30、60、90、120、150和180分钟采集动脉血样本,测定实测丙泊酚浓度(Cm)。在使用69例患者的校正Cp计算调整公式后,我们将校正后的Cp应用于另外5例肥胖患者。
计算每个时间点的中位性能误差(MDPE)和中位绝对性能误差(MDAPE)以测量偏差。
我们分析了69例个体的333份样本。BMI与Cm之间存在显著相关性,肥胖患者的Cm往往大于4.0μg/ml。我们的新方法将MDPE和MDAPE分别从20至40的范围改善至-11.3至-1.8和8.8至11.5的范围。
BMI影响丙泊酚血药浓度,导致在使用Marsh模型评估丙泊酚浓度时肥胖患者有丙泊酚过量的可能性。我们使用校正Cp的新方法可能会改善肥胖日本患者中的这种偏差。